Edwards Lifesciences Corporation (EW)
Largest Insider Buys in Sector
EW Stock Price History Chart
EW Stock Performance
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, …
Insider Activity of Edwards Lifesciences Corporation
Over the last 12 months, insiders at Edwards Lifesciences Corporation have bought $49,753 and sold $42.18M worth of Edwards Lifesciences Corporation stock.
On average, over the past 5 years, insiders at Edwards Lifesciences Corporation have bought $109,049 and sold $82.45M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Zovighian Bernard J (CEO) — $49,753.
The last purchase of 580 shares for transaction amount of $49,753 was made by Zovighian Bernard J (CEO) on 2024‑05‑06.
List of Insider Buy and Sell Transactions, Edwards Lifesciences Corporation
| 2024-11-05 | Sale | Global President TAVR & Surg | 25,000 0.0041% | $65.91 | $1.65M | -0.10% | ||
| 2024-10-15 | Sale | CVP,Strategy/Corp Development | 5,000 0.0009% | $69.51 | $347,534 | -0.62% | ||
| 2024-09-11 | Sale | CVP,Strategy/Corp Development | 5,000 0.0008% | $66.77 | $333,826 | +2.04% | ||
| 2024-08-20 | Sale | CVP, TMTT | 1,250 0.0002% | $69.95 | $87,438 | -1.71% | ||
| 2024-08-14 | Sale | CVP,Strategy/Corp Development | 5,000 0.0008% | $66.08 | $330,420 | 0.00% | ||
| 2024-07-11 | Sale | CVP, JAPAC | 500 <0.0001% | $94.18 | $47,090 | 0.00% | ||
| 2024-07-10 | Sale | CVP,Strategy/Corp Development | 5,000 0.0008% | $93.29 | $466,474 | 0.00% | ||
| 2024-06-20 | Sale | CVP, Chief Financial Officer | 5,625 0.0009% | $87.51 | $492,258 | -23.24% | ||
| 2024-06-20 | Sale | CVP, JAPAC | 535 <0.0001% | $90.00 | $48,150 | -23.24% | ||
| 2024-06-12 | Sale | CVP,Strategy/Corp Development | 5,000 0.0008% | $87.54 | $437,697 | -22.18% | ||
| 2024-05-30 | Sale | CEO | 8,617 0.0014% | $87.68 | $755,539 | -21.90% | ||
| 2024-05-21 | Sale | CVP, Chief Financial Officer | 5,625 0.0009% | $90.45 | $508,803 | -23.85% | ||
| 2024-05-10 | Sale | CVP,Strategy/Corp Development | 5,000 0.0008% | $87.81 | $439,038 | -19.98% | ||
| 2024-05-07 | Sale | CVP, JAPAC | 857 0.0001% | $85.60 | $73,359 | -19.05% | ||
| 2024-05-06 | CEO | 580.26 <0.0001% | $85.74 | $49,753 | -18.17% | |||
| 2024-05-02 | Sale | director | 29,350 0.0049% | $84.77 | $2.49M | -18.16% | ||
| 2024-05-01 | Sale | CVP, EMEACLA and JAPAC | 14,400 0.0024% | $84.21 | $1.21M | -17.16% | ||
| 2024-04-30 | Sale | CVP, Chief Financial Officer | 7,250 0.0012% | $85.80 | $622,062 | -17.36% | ||
| 2024-04-09 | Sale | CVP, JAPAC | 857 0.0001% | $92.34 | $79,135 | -9.24% | ||
| 2024-04-08 | Sale | CVP, EMEACLA | 14,400 0.0024% | $92.32 | $1.33M | -8.32% |
Insider Historical Profitability
| Zovighian Bernard J | CEO | 68218 0.0113% | $65.85 | 1 | 6 | |
| GALLAHUE KIERAN | director | 67219 0.0112% | $65.85 | 2 | 2 | +27.32% |
| Szyman Catherine M. | CVP, Critical Care | 34814 0.0058% | $65.85 | 1 | 56 | +31.99% |
| VALERIANI NICHOLAS J | director | 63811 0.0106% | $65.85 | 1 | 1 | <0.0001% |
| PYOTT DAVID E I | director | 48429 0.008% | $65.85 | 1 | 6 | +10.01% |
Institutional Investor Ownership
| The Vanguard Group | $5.06B | 8.79 | 52.96M | +1.15% | +$57.43M | 0.09 | |
| BlackRock | $5.01B | 8.7 | 52.42M | +0.47% | +$23.59M | 0.11 | |
| State Street | $2.56B | 4.44 | 26.78M | -0.67% | -$17.19M | 0.11 | |
| BNY Mellon | $1.81B | 3.15 | 18.97M | +9.49% | +$157.18M | 0.34 | |
| Brown Advisory | $1.59B | 2.76 | 16.64M | -8.5% | -$147.67M | 2.13 |